Human Genome Sciences announced that it has completed enrollment and initial dosing ahead of schedule in ACHIEVE 1, the first of two pivotal Phase III trials of Albuferon in combination with ribavirin in treatment-naïve patients with chronic hepatitis C.
Human Genome Sciences and Novartis are codeveloping Albuferon (albinterferon alfa-2b) under an exclusive worldwide agreement made in June 2006.
According to Human Genome Sciences, 1,331 patients at 150 clinical sites in 12 countries have been enrolled and randomized in ACHIEVE 1. ACHIEVE 2/3 was initiated in February, and will enroll and randomize a minimum of 918 patients with genotypes 2 and 3 chronic hepatitis C, the company added. read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment